acyclovir Side Effects
Also known as: Zovirax
Analysis of 109,698 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
109,698
Death-Related
13,944
12.7% of reports
Hospitalizations
40,651
37.1% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 13,944 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 4,656 |
| PNEUMONIA | 1,070 |
| SEPSIS | 977 |
| OFF LABEL USE | 916 |
| DRUG INEFFECTIVE | 843 |
| PLASMA CELL MYELOMA | 784 |
| PYREXIA | 728 |
| RESPIRATORY FAILURE | 677 |
| SEPTIC SHOCK | 657 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 536 |
| DISEASE PROGRESSION | 528 |
| FEBRILE NEUTROPENIA | 512 |
| THROMBOCYTOPENIA | 504 |
| DIARRHOEA | 465 |
| RENAL FAILURE | 447 |
| NEUTROPENIA | 431 |
| ANAEMIA | 423 |
| INFECTION | 420 |
| PLATELET COUNT DECREASED | 415 |
| ACUTE KIDNEY INJURY | 396 |
Reactions in Hospitalization Reports
Top reactions in 40,651 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| PNEUMONIA | 4,416 |
| PYREXIA | 3,261 |
| DIARRHOEA | 2,437 |
| FEBRILE NEUTROPENIA | 2,197 |
| NAUSEA | 2,046 |
| FATIGUE | 2,021 |
| OFF LABEL USE | 1,955 |
| DYSPNOEA | 1,846 |
| ACUTE KIDNEY INJURY | 1,618 |
| ASTHENIA | 1,564 |
| SEPSIS | 1,563 |
| VOMITING | 1,557 |
| DRUG INEFFECTIVE | 1,501 |
| FALL | 1,387 |
| ANAEMIA | 1,373 |
| NEUTROPENIA | 1,329 |
| PLATELET COUNT DECREASED | 1,316 |
| THROMBOCYTOPENIA | 1,235 |
| HEADACHE | 1,197 |
| HYPOTENSION | 1,160 |
Nearby — Related Medications
What the FAERS Data Reveals About acyclovir Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 109,698 voluntary reports linked to acyclovir and its brand equivalents (Zovirax), spanning 2003 through 2025. Of those, 13,944 (12.7%) listed death as an outcome and 40,651 (37.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 50% were female and 50% male; age distribution skews toward 45-64, with 23,378 reports in that bracket. The single most reported reaction is fatigue with 7,612 submissions, followed by diarrhoea and off label use.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.